(Updated June 2021)
There are a confusing number of SUSTAIN phase 3 trials either completed or in process, investigating the once-weekly injectable glucagon-like peptide-1 analog semaglutide in patients with type 2 diabetes. The trials are all sponsored by the drug-maker, Novo Nordisk.
Here is our guide to the 15 trials launched to date, which are complete, and which have so far been published in a peer-reviewed journal.
SUSTAIN 1: Published
|Trial population: type 2 diabetes||Comparator treatment: placebo|
The SUSTAIN 1 findings were published in The Lancet Diabetes & Endocrinology in January 2017. They showed that, during 30 weeks of treatment, patients given semaglutide had significantly larger reductions in glycated hemoglobin and in bodyweight than those given placebo.
SUSTAIN 2: Published
|Trial population: type 2 diabetes, taking metformin and/or thiazolidinediones||Comparator treatment: sitagliptin|
SUSTAIN 2, also published in The Lancet Diabetes & Endocrinology, in April 2017, was a head-to-head study of weekly injectable semaglutide versus daily oral sitagliptin in patients already taking metformin and/or thiazolidinediones.
The findings showed significantly larger reductions in HbA1c with semaglutide, as well as larger reductions in bodyweight.
SUSTAIN 3: Published
|Trial population: type 2 diabetes, taking metformin and/or thiazolidinedione and sulfonylureas||Comparator treatment: extended-release exenatide|
The SUSTAIN 3 findings, published in Diabetes Care, show that semaglutide 1.0 mg produced a larger HbA1c reduction than exenatide 2.0 mg, of 1.5% versus 0.9% over 56 weeks. However, the researchers cautioned that this could have been influenced by the “more complex device” used to administer exenatide.
SUSTAIN 4: Published
|Trial population: type 2 diabetes; insulin-naïve, taking metformin with/without sulfonylurea||Comparator treatment: insulin glargine|
SUSTAIN 4, again published in The Lancet Diabetes & Endocrinology, pitted semaglutide against insulin during 30 weeks of treatment. The trial met the noninferiority endpoint and, in fact, patients achieved significantly larger HbA1c reductions with semaglutide than insulin, although the researchers noted that insulin titration may not have been optimal.
SUSTAIN 5: Published
|Trial population: type 2 diabetes, taking basal insulin with/without metformin||Comparator treatment: placebo|
The SUSTAIN 5 findings are published in The Journal of Clinical Endocrinology & Metabolism. They reveal significant 1.4% (15.8 mmol/mol) and 1.8% (20.2 mmol/mol) reductions in HbA1c during 30 weeks of treatment with 0.5 and 1.0 mg semaglutide, respectively, versus a 0.1% (1.0 mmol/mol) reduction with placebo.
SUSTAIN 6: Published
|Trial population: type 2 diabetes at high cardiovascular risk, excluding those using other GLP-1 analogs or dipeptidyl peptidase 4 inhibitors||Comparator treatment: placebo|
The results of SUSTAIN 6, published in The New England Journal of Medicine, showed a significant 26% reduction in the composite primary endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. This endpoint occurred in 6.6% of patients taking semaglutide and 8.9% of those taking placebo during a median of 2.1 years of follow-up.
SUSTAIN 7: Published
|Trial population: type 2 diabetes on stable metformin treatment||Comparator treatment: dulaglutide|
The SUSTAIN 7 findings, published in The Lancet Diabetes & Endocrinology, show that semaglutide produced better glycemic control than competitor GLP-1 receptor agonist dulaglutide. The respective average HbA1c reductions were 1.5% versus 1.1% at low doses of 0.5 and 0.75 mg and 1.8% versus 1.4% at high doses of 1.0 and 1.5 mg. Patients taking semaglutide also lost more weight than those taking the equivalent dose of dulaglutide.
SUSTAIN 8: Published
|Trial population: type 2 diabetes on stable metformin treatment||Comparator treatment: canagliflozin|
The SUSTAIN 8 trial – reported in The Lancet Diabetes & Endocrinology – demonstrated a significantly greater reduction in HbA1c levels with semaglutide versus the sodium-glucose cotransporter (SGLT)-2 inhibitor canagliflozin at 1 year, with mean decreases of 1.5% and 1.0%, respectively.
Semaglutide-treated patients also experienced greater weight loss, at an average of 5.3 kg compared with 4.2 kg for those given canagliflozin, but a substudy showed comparable improvements in body composition in both treatment arms.
SUSTAIN 9: Published
|Trial population: type 2 diabetes, taking SGLT-2 inhibitor with or without metformin or sulfonylurea||Comparator treatment: placebo|
The findings of this trial, published in The Lancet Diabetes & Endocrinology, support the use of semaglutide as an add-on to SGLT-2 inhibitor treatment. During 30 weeks of treatment in 302 patients, those given semaglutide achieved a 1.4% larger HbA1c reduction than those given placebo, and they lost more weight.
SUSTAIN 10: Published
|Trial population: type 2 diabetes on stable treatment with up to three oral antidiabetics||Comparator treatment: liraglutide|
The SUSTAIN 10 findings favor the use of semaglutide over the GLP-1 receptor agonist liraglutide as an add-on therapy to oral antidiabetic drugs. As reported in Diabetes & Metabolism, glycemic control was better with semaglutide, with an average HbA1c reduction of 1.7% versus 1.0% at week 30, and average weight loss was greater, at 5.8 and 1.9 kg, respectively.
SUSTAIN 11: Completed, not yet published
|Trial population: type 2 diabetes, taking basal insulin plus metformin||Comparator treatment: insulin aspart|
This trial has recruited 2275 people and aims to determine whether initiating semaglutide is a viable alternative to starting a prandial insulin for people with type 2 diabetes whose blood glucose is poorly controlled with basal insulin plus metformin.
SUSTAIN FORTE: Completed
|Trial population: type 2 diabetes, taking metformin with/without a sulfonylurea||Comparator treatment: semaglutide 2.0 mg|
In this trial, 961 participants were randomly assigned to receive semaglutide 1.0 or 2.0 mg, the latter given as two injections of 1.0 mg, for 40 weeks.
As reported at the virtual ADA 81st Scientific Sessions, the higher dose achieved a significantly greater HbA1c reduction in trial product estimand analysis, of 2.2 percentage points compared with 1.9 percentage points for the standard dose. The higher dose also resulted in a significantly larger bodyweight reduction, of 6.9 versus 6.0 kg.
SUSTAIN – CHINA MRCT: Published
|Trial population: patients with type 2 diabetes, taking metformin||Comparator treatment: sitagliptin|
Similar to SUSTAIN 2, this trial tested semaglutide 0.5 and 1.0 mg against sitagliptin, but in a patient population drawn from China, Hong Kong, Brazil, Taiwan, Ukraine, South Korea, and South Africa.
As reported in Diabetes, Obesity and Metabolism, during 30 weeks of treatment semaglutide produced significantly greater reductions in HbA1c than sitagliptin, at estimated treatment differences of –0.51% and –0.85% for the 0.5 and 1.0 mg doses, respectively. Participants taking semaglutide were also more likely to achieve HbA1c targets than those taking sitagliptin, and they lost significantly more weight.
SUSTAIN (Japan): Published
|Trial population: Japanese type 2 diabetes patients on stable oral antidiabetic medication||Comparator treatment: oral antidiabetic, selected according to baseline medication|
Patients in this trial remained on their baseline treatment and were randomly assigned to receive either semaglutide or investigators’ choice of oral antidiabetic agent. The findings published in Diabetes, Obesity and Metabolism show significantly larger reductions in HbA1c with semaglutide 0.5 and 1.0 mg versus other antidiabetics, at 1.7% and 2.0% versus 0.7%, respectively. Patients on semaglutide also lost weight, compared with a slight increase in the comparator group.
SUSTAIN (Japan, sitagliptin): Published
|Trial population: Japanese patients with type 2 diabetes treated with lifestyle management or monotherapy||Comparator treatment: sitagliptin|
In this trial, published in Diabetes, Obesity and Metabolism, Japanese patients received weekly semaglutide 0.5 or 1.0 mg or daily oral sitagliptin 100 mg (after washout of pre-existing treatments). Glycated hemoglobin fell by 1.9–2.2% with semaglutide versus 0.7% with sitagliptin, which was a significant difference. There were more adverse effects among patients treated with semaglutide than sitagliptin, most commonly constipation, nausea, and diarrhea.